GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » 23andMe Holding Co (NAS:ME) » Definitions » EV-to-FCF

23andMe Holding Co (23andMe Holding Co) EV-to-FCF : -0.41 (As of May. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is 23andMe Holding Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, 23andMe Holding Co's Enterprise Value is $79.0 Mil. 23andMe Holding Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-194.3 Mil. Therefore, 23andMe Holding Co's EV-to-FCF for today is -0.41.

The historical rank and industry rank for 23andMe Holding Co's EV-to-FCF or its related term are showing as below:

ME' s EV-to-FCF Range Over the Past 10 Years
Min: -60.37   Med: -4.35   Max: -0.15
Current: -0.41

During the past 4 years, the highest EV-to-FCF of 23andMe Holding Co was -0.15. The lowest was -60.37. And the median was -4.35.

ME's EV-to-FCF is ranked worse than
100% of 104 companies
in the Medical Diagnostics & Research industry
Industry Median: 27.875 vs ME: -0.41

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), 23andMe Holding Co's stock price is $0.5023. 23andMe Holding Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.110. Therefore, 23andMe Holding Co's PE Ratio for today is At Loss.


23andMe Holding Co EV-to-FCF Historical Data

The historical data trend for 23andMe Holding Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

23andMe Holding Co EV-to-FCF Chart

23andMe Holding Co Annual Data
Trend Mar20 Mar21 Mar22 Mar23
EV-to-FCF
- - -6.93 -4.24

23andMe Holding Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.80 -4.24 -3.44 -1.86 -1.43

Competitive Comparison of 23andMe Holding Co's EV-to-FCF

For the Diagnostics & Research subindustry, 23andMe Holding Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


23andMe Holding Co's EV-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, 23andMe Holding Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where 23andMe Holding Co's EV-to-FCF falls into.



23andMe Holding Co EV-to-FCF Calculation

23andMe Holding Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=78.973/-194.275
=-0.41

23andMe Holding Co's current Enterprise Value is $79.0 Mil.
23andMe Holding Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-194.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


23andMe Holding Co  (NAS:ME) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

23andMe Holding Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.5023/-1.110
=At Loss

23andMe Holding Co's share price for today is $0.5023.
23andMe Holding Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.110.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


23andMe Holding Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of 23andMe Holding Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


23andMe Holding Co (23andMe Holding Co) Business Description

Traded in Other Exchanges
N/A
Address
349 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment include Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
Executives
Kathy L Hibbs officer: See Remarks C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
William G Richards officer: Head of Therapeutics Discovery 160 KELLY AVE, HALF MOON BAY CA 94019
Richard H Scheller director C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Joseph Anthony Selsavage officer: Interim CFO 490 HILL STREET, APT 5, SAN FRANCISCO CA 94114
Kenneth J. Hillan officer: Head of Therapeutics C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Evan Lovell director, officer: Chief Financial Officer 27 SOUTH PARK STREET, SUITE 200, SAN FRANCISCO CA 94107
Hernandez Sandra R Md director BLACKBAUD INC, 2000 DANIEL ISLAND DRIVE, CHARLESTON SC 29492
Paul D Johnson officer: VP, General Manager-Consumer 440 N BARRANCA AVE #3550, COVINA CA 91723
Tracy Keim officer: See Remarks 6107 ARROWROOT LANE, RANCHO PALOS VERDES CA 90275
Steven Lemon officer: Vice President, Engineering 1020 CHERRY AVENUE, SAN JOSE CA 95125
Steven J Schoch officer: See Remarks 2748 BUSH STREET, SAN FRANCISCO CA 94115
Frederick Mark Kohler officer: Vice President, People 1004 UNION STREET, ALAMEDA CA 94501
Sequoia Capital Global Growth Ii Principals Fund, L.p. 10 percent owner 2800 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Abeec 2.0, Llc 10 percent owner 171 MAIN STREET, SUITE 259, LOS ALTOS CA 94022
Anne Wojcicki director, 10 percent owner, officer: Chief Executive Officer C/O AJAX I HOLDINGS, LLC, 667 MADISON AVENUE, NEW YORK NY 10606